Effects of oral administration of type i interferons on experimental autoimmune encephalomyelitis

Interferon Therapy of Multiple Sclerosis

Volumn , Issue , 1997, Pages 245-286

  Brod, Staley A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343329932     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (158)

1. Hafler DA, Brod SA, Weiner HL. Immunoregulation in multiple sclerosis. Res Immunol 1989; 140:233-239.
2. Hafler DA, Brod SA, Weiner HL. Experimental approaches to specific immunotherapy in multiple sclerosis. In: R Ruduck, A Goodkin eds. Treatment of Multiple Sclerosis: Trial Design, Results, and Future Perspectives. London: Springer-Verlag, 1992:301-308.
3. McFarlin D, McFarland H. Multiple Sclerosis. N Engl J Med 1982; 307: 1183-1188.
4. Waksman B, Reynolds WE. Multiple sclerosis as a disease of immune regulation. Proc Soc Exp Biol Med 1984; 175:282-294.
5. Antel JP, Freedman MS, Brodsovsky S, Francis GS, Duquette P. Activated suppressor cell function in severely disabled patients with multiple sclerosis. Ann Neurol 1989; 25:204-207.
6. Brod SA, Scott M. Defective CD3 mediated proliferation and LPS responsiveness in multiple sclerosis. Autoimmunity 1994; 17:143-148.
7. Brod SA, Khan M, Bright J, Sriram S, Marshall GD, Henninger EM, Kerman RH, Wolinsky JS. Decreased CD3 mediated IFN-y production in relapsing- remitting multiple sclerosis. Ann Neurol 1995; 37:546-549.
8. Isaacs A, Lindenmann J. Virus Interference. I. The interferon. Proc R Soc Lond (Biol), 1957; 147:258-267.
9. Johnson HM, Baron S. Evaluation of effects of interferon and interferon inducers on the immune response. Pharmacol Ther 1977; 1:349-367.
10. Trotta PP, Narula SK. Interferon genes: In: Baron S, Dianzani F, Stanton GJ, Fleischmann WR, eds. Interferon System. Austin, TX: UT Press, 1987: 137-143.
11. Aguet M, Mogensen KE. Interferon receptors. In: Gresser I, ed. Interferons. Vol. 5. New York: Academic Press, 1983:1-22.
12. Rashidbaigi A, Pestka S. Interferons: Protein structure. In: Baron S, Dianzani F, Stanton GJ, Fleischmann WR, eds. The Interferon System. Austin TX: UT Press, 1987:149-168.
13. Zoon KC. Human interferons: Structure & function In: Interferon 9. London: Academic Press, 1987:1-12.
14. Baglioni C. 2',5'-oligo(A) pathway of interferon action. In: Baron S, Dianzani F, Stanton GJ, Fleischmann WR, eds. The Interferon System. Austin TX: UT Press, 1987:365-371.
15. Dolei A, Ameglio F. Effects of IFN on phenotypic expression by cells. In: Baron S, Dianzani F, Stanton GJ, Fleischmann WR, eds. The Interferon System. Austin TX: UT Press, 1987:271-277.
16. Pestka S, Langer J, Zoon KC, Samuel CE. Interferons and their actions. Ann Rev Biochem 1987; 56:727-777.
17. Balkwill FR. The regulatory role of interferons in the human immune response. In: Taylor-Papadimitriou, ed. Interferons: Their Impact in Biology of Medicine Oxford Medical, 1985:61-80.
18. Hertzog PJ, Emery P, Cheetham BF, MacKay IR, Linnane AW. Interferons in rheumatoid arthritis: alterations of production and response related to disease activity. Clin Immunol Immunopathol 1988; 48:192-201.
19. Seitz M, Napierski I, Augustin R, Hunstein W, Kirchner H. Reduced production of interferon alpha and interferon gamma in leukocyte cultures from patients with active rheumatoid arthritis. Scand J Rheumatol 1987; 16: 257-262.
20. Kapp A, Gillitzer R, Kirchner H, Schopf E. Production of interferon and lymphoproliferative response in whole blood cultures derived from patients with atopic dermatitis. Arch Dermatol Res 1987; 279(suppl: S):55-58.
21. Kapp A, Gillitzer R, Kirchner H, Schopf E. Decreased production of interferon in whole blood cultures derived from patients with psoriasis. J Invest Dermatol 1988; 90:511-514.
22. Hertzog PJ, Wright A, Harris G, Linnane AW, Mackay IR. Intermittent interferonemia and interferon responses in multiple sclerosis. Clin Immunol Immunopathol 1991; 58:18-32.
23. Neighbour PA, Bloom BR. Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis. Proc Natl Acad Sci USA 1979; 76:476-480.
24. Maruo Y. Interferon production and natural killer activity of peripheral blood lymphocytes obtained from patients with multiple sclerosis. Hokkaido J Med Sci 1988; 63:521-533.
25. Struyf NJ, Snoeck HW, Bridts CH, De Clerck LS, Stevens WJ. Natural killer cell activity in Sjogren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes. Ann Rheum Dis 1990; 49:690-693.
26. Negishi K, Gupta S, Chandy KG, Waldeck N, Kershnar A, Buckingham B, Charles MA. Interferon responsiveness of natural killer cells in type I human diabetes. Diabetes Res. 1988; 7:49-52.
27. Thoen J, Waalen K, Forre O. Natural killer (NK) cells at inflammatory sites of patients with rheumatoid arthritis and IgM rheumatoid factor positive polyarticular juvenile rheumatoid arthritis. Clin Rheumatol 1987; 6:215-225.
28. Kastrukoff LF, Morgan NG, Aziz TM, Zecchini D, Berkowitz J, Paty DW. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon. J Neuroimmunol 1988; 20: 15-23.
29. Vranes Z, Poljakovic Z, Marucic M. Natural killer cell number and activity in multiple sclerosis. J Neurol Sci 1989; 94:115-123.
30. Rice GPA, Casali P, Merigan TC, Oldstone MBA. Natural killer cell activity in patients with multiple sclerosis given alpha interferon. Ann Neurol 1983; 14:333-338.
31. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Neurology 1990; 27:207-210.
32. Noronha A, Toscas A, Arnason BG, Jensen MA. Interferon beta augments in vivo suppressor function in multiple sclerosis (abstr). Neurology 1994; 2(suppl):212.
33. Fog T. Interferon treatment of multiple sclerosis patients: a pilot study. In: Boese A, ed. Search for a Cause of Multiple Sclerosis and Other Chronic Diseases of the CNS. Weinheim: Verlag Chemie, 1980:491-493.
34. Ververken D, Carton H, Billiau A. Intrathecal administration of interferon in MS patients? In: Karcher D, Lowenthal A, Strosberg AD, eds. Humoral Immunity in Neurological Disease. New York: Plenum Press, 1979: 625-627.
35. Montezuma-de-Carvalho MJ. A treatment for the chronic disabilities of stable multiple sclerosis. Acta Medicotechnica 1983; 31:155-160.
36. Knobler RL, Panitch HS, Braheny SL, Sipe JC, Rice GPA, Huddlestone JR, Francis GS, Hooper CJ, Kamin-Lewis RM, Johnson KP, Oldstone MBA, Merigan TC. Controlled clinical trial of systemic alpha interferon in multiple sclerosis. Neurology 1983; 34:1273-1279.
37. Kamin-Lewis RM, Panitch HS, Johnson KP. Leucocytes from multiple sclerosis patients respond to α- and γ-interferons. J Neuroimmunol 1985; 9:221-227.
38. Panitch HS, Francis GS, Hooper CJ, Merigan TC, Johnson KP. Serial immunological studies in multiple sclerosis patients treated systemically with human interferon alpha. Ann Neurol 1985; 18:434-438.
39. Panitch HS. Systemic alpha-interferon in multiple sclerosis: Long term patient follow-up. Arch Neurol 1987; 44:61-63.
40. Knobler RL. Systemic interferon therapy of multiple sclerosis: the pros. Neurology 1988; 38:58-61.
41. Kastrukoff LF, Oger JJ, Hashimoto SA, Sacks SL, Li DK, Palmer MR, Koopmans RA, Petkau AJ, Berkowitz J, Paty DW. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 1990; 40:479-486.
42. Jacobs L, O'Malley JA, Freeman A, Ekes R. Intrathecal interferon in multiple sclerosis. Arch Neurol 1982; 39:609-615.
43. Jacobs L, O'Malley JA, Freeman A, Ekes R, Reese PA. Intrathecal interferon in the treatment of multiple sclerosis. Arch Neurol 1985; 42:841-847.
44. Jacobs L, Herndon R, Salazar AM, Reese PA, Freeman A, Josofewicz R, Cuetter A, Husain F, Smith WA, Ekes R, O'Malley JA. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis, results of multicenter, double-blinded study. Arch Neurol 1987; 44:589-595.
45. Camenga DL, Johnson KP, Alter M, Engelhardt CD, Fishman PS, Greenstein JI, Haley AS, Hirsch RL, Kleiner JE, Kofie, VY, Koski CL, Margulies SL, Panitch HS, Valero R. Systemic recombinant alpha 2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 1986; 43: 1239-1245.
46. Hirsch RL, Johnson KP. Placebo induced enhancement of natural killer cell activity in a double blind trial of recombinant alpha-2 interferon in multiple sclerosis patients. In: Spector NH, ed. Neuroimmunomodulation. Proceedings of the first International Workshop of Neuroimmunomodulation. Bethesda, MD. IWGN, 1985:219-226.
47. Hirsch RL, Johnson KP. The effect of long term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis. J Interferon Res 1986; 6:171-177.
48. IFNB MS Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43:655-661.
49. IFNB MS Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43:662-667.
50. Durelli L, Bongioanni MR, Cavallo R, Ferraro B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M, Bergnami L, Bergamasco B. Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406-413.
51. Jacobs L, Cookfair D, Rudick R, Herndon R, Richert J, Salazar A, Fischer J, Granger C, Simon J, Goodkin D, and the MS Collaborative Group. Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis. Ann Neurol 1994; 36(2):259.
52. Schafer TW, Lieberman M, Cohen M, Came P. Interferon administered orally: protection of neonatal mice from lethal virus challenge. Science 1972; 176:1326-1327.
53. Cummins JM, Tompkins MB, Olsen RG, Tompkins WA, Lewis MG. Oral use of human alpha interferon in cats. J Biol Response Modifiers 1988; 7: 513-523.
54. Young AS, Maritim AC, Karuiki DP, Stagg DA, Wafula JM, Mutugi JJ, Cummins JM, Richards AB, Burns C. Low-dose oral administration of human interferon alpha can control the development of Theileria parva infection in cattle. J Parasitol 1990; 101 (Pt 2):201-209.
55. Streuli M, Hall A, Boll W, Stewart WE, Nagat S, Weisman C. Target cell specificity of two species of human interferon-a produced from Escherichia coli and of hybrid molecules derived from them. Proc Natl Acad Sci USA 1981; 78:2848-2852.
56. Stanton G, Hughes T, Heard H, Georgiades J, Whorton E. Modulation of a natural virus defense system by low concentrations of interferons at mucosal surfaces. J Interferon Res 1990; 10:(S-1)S99.
57. Lecce JG, Cummins JM, Richards AB. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. J Mol Biother 1990; 2:211-216.
58. Koech DK, Obel AO, Minowada J, Hutchinson VA, Cummins JM. Low dose oral alpha interferon therapy for patients seropositive for human immunodeficiency virus type I (HIV-I). Mol Biother 1990; 2:91-95.
59. Young AS, Cummins JM. The history of interferon and its use in animal therapy. East Afr Med J 1990; 67(suppl 2):SS31-63.
60. Bocci V. Is interferon effective after oral administration? The state of the art. J Biol Reg Homeostasis Agents 1990; 4:81-83.
61. Bocci V. Catabolism of therapeutic proteins and peptides with implications for drug delivery. Adv Drug Del Rev 1990; 4:149-169.
62. Bocci V. Absorption of cytokines via the oropharyngeal associated lymphoid tissues-Does an unorthodox route improve the therapeutic index of interferon? Clin Pharmacokinet 1991; 21:411-417.
63. Bocci V. Immunomodulators as local hormones: new insights regarding their clinical utilization. J Biol Res Mod 1985; 4:340-352.
64. Cantell K, Pyhala L. Circulating interferon in rabbits after administration by different routes. J Gen Virol 1973; 20:97-104.
65. Hanley D, Wironowska-Stewart M, Stewart II WE. Pharmacology of interferons. I. Pharmacologic distinctions between human leucocyte and fibroblast interferons. Int J Immunopharmacol 1979; 1:219-225.
66. Stewart II WE, Wironowska-Stewart M. Characterization of human interferon types and subtypes. In: Khan A, Hill NO, Dorn GL, eds. Interferon. Properties and Clinical Uses. Dallas: L. Fikes Press, 1980:111-120.
67. Ruegg CL, Strand M. Identification of a decapeptide region of human interferon a with antiproliferative activity and homology to an immunosuppressive sequence of the retroviral transmembrane protein P15E. J Interferon Res 1990; 10:621-626.
68. Waine GJ, Tymms MJ, Brandt ER, Cheetham BF, Linnane AW. Structurefunction study of the region encompassing residues 26-40 of human interferon- a4: identification of residues important for antiviral and antiproliferative activities. J Interferon Res 1992; 12:43-48.
69. Paulesu L, Corradeschi F, Nicoletti C, Bocci V. Oral administration of human recombinant interferon-az in rats. Int J Pharmaceut 1988; 46: 199-202.
70. Bocci V, Corradeschi F, Naldini A, Lencioni E. Enteric absorbtion of human interferon a and 0 in the rat. Int J Pharmaceut 1988; 46:199-202.
71. Fleischmann WR, Koren S and Fleischmann CM. Oral administered inter ferons exert their white blood cell suppressive effects via a novel mechanism. Proc Soc Exp Biol Med 1992; 201:199-207.
72. Gibson DM, Cotler S, Spiegel HE, Colburn WA. Pharmokokinetics of recombinant leucocyte A interferon following various routes and modes of administration to the dog. J Interferon Res 1985; 5:403-408.
73. Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant leucocyte A interferon following IV infusion and bolus, IM, and PO administration to african green monkeys. J Interferon Res 1984; 4:399-409.
74. Witt PJ, Goldstein D, Storer BE, Grossberg SE, Flashner M, Colby CB, Borden EC. Absence of biological effects of orally administered interferon- Pser. J Interferon Res 1992; 12:411-413.
75. Bocci V. Roles of interferon produced in physiological conditions. A speculative review. Immunology 1988; 64:1-9.
76. Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PJ, Teitlebaum AP, Smalley RV, Borden EC. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-j3 serine. J Natl Cancer Inst 1989; 81:1061-1068.
77. Blalock JE, Baron S, Johnson HM, Stanton GJ. Transmission of interferoninduced activities by cell to cell communication. Tex Rep Biol Med 1982; 41:344-349.
78. Alvord EC, Shaw CM, Huby S, Kies MW. Encephalitogen-induced inhibition of experimental allergic encephalomyelitis: prevention, suppression and therapy. Ann NY Acad Sci 1965; 122:333-345.
79. Johns LD, Flanders KC, Ranges GE, and Sriram S. Successful therapy of experimental allergic encephalomyelitis with transforming growth factorpi J Immunol 1991; 147:1792-1796.
80. Hertz F, Deghenghi R. Effect of rat and a-human interferons on hyperacute experimental allergic encephalomyelitis in rats. Agents Actions 1985; 16: 397-403.
81. Karpus WJ, Swanborg RH. CD4 + suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-β. J Immunol 1991; 146: 1163-1168.
82. Abreu SL. Suppression of experimental allergic encephalomyelitis by interferon. Immunol Commun 1982; 11:1-7.
83. Abreu SL, Tondreau J, Levine S, Sowinski R. Inhibition of passive localized experimental allergic encephalomyelitis by interferon. Int Arch Allergy Appl Immunol 1983; 72:30-33.
84. Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with disease. J Immunol 1992; 149:2496-2505.
85. Hutchison VA, Angenend JL, Mok WL, Cummins JM, Richards AB. Chronic recurrent aphthous stomatitis: oral treatment with low dose interferon alpha. Mol Biother 1990; 2:160-164.
86. Brod SA, Scott M, Burns DH. 1994. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type I interferons. J Interferon Res. In Press.
87. Tabata Y, Uno K, Yamaoka T, Ikada Y and Muramatsu S. Effects of recombinant alpha interferon gelatin conjugate on in vivo murine tumor cell growth. Cancer Res 1991; 51:5532-5538.
88. Shibita M and Blatteis CM. Human recombinant tumor necrosis factor and interferon affect the activity of neurons in the organum vasculosum lamina terminalis. Brain Res 1991; 562:323-326.
89. Dennis MJ, Thomas LH, and Stott EJ. Effects of recombinant human alpha A interferon in gnotobiotic calves challenged with respiratory syncyntial virus. Res Vet Sci 1991; 50:222-228.
90. Horisberger MA, and Gunst MC. Interferon induced proteins: identification of Mx proteins in various mammalian species. Virology 1991; 180: 185-190.
91. Weiss RC, Cummins JM, Richards AB. Low-dose orally administered interferon alpha treatment for feline leukemia virus infection. J Am Vet Med Assoc 1991; 199:1477-1481.
92. Weiss RC and Oostrom-Ram T. Effects of recombinant human interferon alpha in vitro and in vivo on mitogen induced lymphocyte blastogenesis in cats. J Clin Immunol Immunopathol 1990; 24:147-157.
93. Kawade Y. The interferon system in the mouse. In: Baron S, Dianzoni F, Stanton GJ, Fleischmann WR, eds. The Interferon System. Austin, TX: UT Press, 1987:169-175.
94. Blalock JE, Baron S. Interferon induced transfer viral resistance between animal cells. Nature 1977; 269:422-425.
95. McDonald AH, Swanborg RH. Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J Immunol 1988; 140:1132-1138.
96. Raine CS, Stone SH. Animal models for multiple sclerosis: chronic experimental allergic encephalomyelitis in inbred guinea pigs. N.Y. State J Med 1977; 77:1693-1696.
97. Wisniewski HM, Keith AB. Chronic relapsing experimental allergic encephalomyelitis: An experimental model of multiple sclerosis. Ann Neurol 1977; 1:144-148.
98. Feuer C, Prentice DE, Cammisuli S. Chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. J Neuroimmunol. 1985; 10:159-166.
99. Brown AM, McFarlin DE. Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest 1981; 45:278-284.
100. Miller SD, Clatch RJ, Pevear DC, Trotter JL, Lipton HL. Class II restricted T cell response in Theiler's murine emcephalomyelitis virus induced demyelinating disease. J Immunol 1987; 138:3776-3784.
101. Weber H, Valenzuela D, Lujber G, Gubler M, Weissman C. Single amino acid changes that render human IFN-a2 biologically active on mouse cells. EMBO J 1987; 6:591-598.
102. McInnes M, Chambers PJ, Cheetham BF, Beilharz MW, Tymms MJ. Struc ture function studies of interferons-a: amino acid substitutions at the conserved residue tyrosine 123 in human interferons-a. J Interferon Res 1989; 9:305-314.
103. Brod SA, Khan M, Kerman RH, Pappolla M. Oral administration of human or murine IFN-a suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J Neuroimmunol 1995; 58: 61-69.
104. Brod SA, Burns DH. Suppression of relapsing experimental allergic encephalomyelitis in SJL/J mouse by oral administration of type I interferons. Neurology 1994; 44:1144-1148.
105. Brod SA, Khan M. 1994. Oral administration of human or murine type I interferons suppresses relapses in chronic relapsing EAE. Cytokine 6(5): 567:A169.
106. Lublin, F. Adoptive transfer of murine relapsing experimental autoimmune encephalomyelitis. Ann Neurol 1985; 17:188-190.
107. Whitham RH, Bourdette DN, Hashim GA, Herndon RM, Ilg RC, Vandenbark AA, Offner H. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer demyelinating relapsing experimental autoimmune encephalomyelitis. J Immunol 1991; 146:101-107.
108. Peters BA, Hinrichs DJ. Passive transfer of experimental allergic encephalomyelitis in the Lewis rat with activated spleen cells: Differential activation with mitogens. Cell Immunol 1982; 69:175-185.
109. Fallis RJ, Raine CS, McFarlin DE. Chronic relapsing experimental allergic encephalomyelitis in SJL/J mice following the adoptive transfer of an epitope- specific T cell line. J Neuroimmunol 1989; 22:93-105.
110. van der Veen RC, Trotter, JL, Clark HB, Kapp JA. The adoptive transfer of chronic experimental allergic encephalomyelitis with lymph nodes sensitized to myelin proteolipid protein. J Neuroimmunol 1989; 21:183-191.
111. Tuohy VK, Lu Z, Sobel RA, Laursen RA, Lees MB. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL/J mice. J Immunol 1989; 142:1523-1527.
112. Greer JM, Kuchroo VJ, Sobel RA, Lees MB. Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL/J mice. J Immunol 1992; 149:783-788.
113. Sobel RA, Tuohy VK, Lu Z, Sobel RA, Laursen RA, Lees MB. Acute experimental allergic encephalomyelitis in the SJL/J mouse induced by a synthetic peptide of myelin proteolipid protein. J Neuropathol Exp Neurol 1990; 49:468.
114. Kennedy MK, Tan L-J, Del Canto MC, Miller SD. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigenspecific tolerance induction. J Immunol 1990; 145:117-126.
115. Kennedy MK, Tan L-J, Del Canto MC, Tuohy VK, Lu Z, Trotter JL, Miller SD. Inhibition of murine autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol 1990; 144:909-915.
116. Brod SA, al-Sabbagh A, Sobel RA, Weiner HL. Suppression of relapsing experimental allergic encephalomyelitis in Lewis rats and strain 13 guinea pigs by oral administration of myelin antigens. Ann Neurol 1991; 29: 615-622.
117. Weiner HL, Friedman A, Miller A, SJ Khoury, DM Dawson, DA Haller. Double blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259:1321-1324.
118. Kadish AS, Tansey FA, Yu GSM, Doyle AT and Bloom BR. Interferon as a mediator of human lymphocyte suppression. J Exp Med 1980; 151: 637-650.
119. Devens BH, Semenuk G, Webb DR. Antipeptide antibody specific for the N-terminal of soluble immune response suppressor neutralizes concavalin A and IFN-induced suppressor cell activity in an in vitro cytotoxic T lymphocyte response. J Immunol 1988; 141:3148-3155.
120. Aune TM, and Pierce CW. Activation of a suppressor T cell pathway by interferon. Proc Natl Acad Sci USA 1982; 79:3808-3812.
121. Schnapper HW, Pierce CW, Aune TM. Identification and initial characterization of Con A and interferon-induced human suppressor factor: evidence for a human equivalent of murine soluble immune response suppressor [SIRS]. J Immunol 1984; 132:2429-2435.
122. Stobo J, Green I, Jackson L and Baron S. Identification of a subpopulation of mouse lymphoid cells required for interferon production after stimulation with mitogens. J Immunol 1974; 112:1589-1593.
123. Weil J, Epstein CJ, Epstein LB, Sedmak JJ, Sabran JL, Grossberg SE. A unique set of polypeptides is induced by gamma interferon in addition to those induced in common with alpha and beta interferon. Nature 1983; 301: 437-439.
124. Mossmann TR, Cherwinski H, Bond MW, Giedlin MA, and Coffman RL. Two types of murine helper T cells. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
125. Kim J, Woods A, Becker-Dunn E, and Bottomly K. Distinct functional phenotypes of cloned Ia-restricted helper T cells. J Exp Med 1985; 162: 188-201.
126. Cher DJ Mosmann TR. Two types of murine helper T cell clone. II. Delayedtype hypersensitivity is mediated by Thl clones. J Immunol 1987; 138: 3688-3694.
127. Boom WH, Liano D, and Abbas AK. Heterogeneity of helper/inducer T lymphocytes II. Effects of interleukin-4 and interleukin-2 producing T cell clones on resting B cells. J Exp Med 1988; 167:1350-1363.
128. Street N, Schumacher JH, Fong TAT, Bass H, Fiorentino DF, Leverach JA, Mosmann TR. Heterogeneity of mouse helper T cells: evidence from bulk cultures and limiting dilution cloning for precursors of Thl and Th2 cells. J Immunol. 1990; 144:1629-1637.
129. Merrill JE, Kono DH, Clayton J, Ando DG, Hinton DR. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc Natl Acad Sci USA 1992; 89:574-578.
130. Brod SA, Benjamin D, Halfer DA. Restricted T cell expression of IL-2/IFNy mRNA in human inflammatory disease. J Immunol 1991; 147:810-815.
131. Yssel H, Shanafelt M-C, Soderberg C, Schneider PV, Anzola J, Peltz G. Borrelia burgdorferai activates a T helper type-1 like T cell subset in Lyme arthritis. J. Exp. Med. 1991; 174:593-601.
132. Haanen J, Malefijt R, Res P, Kraakman, EM, Ottenhoff, THM, deVries, RRP, Spits, H. Selection of a human T helper type I-like T cell subset by Mycobacteria. J Exp Med 1991; 174:583-591.
133. Mossman T, Moore KW. The role of IL-10 in crossregulation of Thl and Th2 responses. Immunol Today 1991; 12:A49-53.
134. Brandtzaeg P. Overview of the mucosal immune system. Curr Top Microbiol Immunol 1989; 146:13-28.
135. Ermak TH, Owen RL. Differential distribution of lymphocytes and accessory cells in Peyer's patches. Anat. Rev. 1986; 215:144-52.
136. Witmer MD, Steinman RM. The anatomy of peripheral lymphoid organs with emphasis on accessory cells: light-microscopy immuno-cytochemical studies of the mouse spleen, lymph node, and Peyer's patch. Am J Anat 1984; 170:465-481.
137. MacDonald TT. Immunosuppression caused by antigen feeding. II. Suppressor T cells mask Peyer's patches B cell priming to orally administered antigen. Eur J Immunol 1983; 13:138-142.
138. Santos LMB, al-Sabbagh A, Londono A, Weiner HL. Oral tolerance to MBP induces TGF-β secreting T cells in Peyer's patch. J Immunol 1993; 150[8, II]: 115A.
139. Mattingly JA. Immunologic suppression after oral administration of antigen. Cell Immunol 1984; 86:45-52.
140. Xu-Amano J, Aicher WK, Taguchi T, Kiyono H, McGhee JR. Selective induction of Th2 cells in murine Peyer's patches by oral immunization. Int Immunol 1992; 4:433-45.
141. Daynes RA, Areneo BA, Dowell TA, Huang K, Dudley D. Regulation of murine cytokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influence over T helper function. J Exp Med 1990; 171:979-996.
142. P (β7): a functional role in Peyer's patch-specific lymphocyte homing. Proc Natl Acad Sci USA 1992; 89:8254-8258.
143. Chin YH, Cai JP, Xu XM. TGF-02 and IL-4 regulate adhesiveness of Peyer's patch HEV cells for lymphocytes. J Immunol 1992; 148:1106-12.
144. LeFrancois L. IEL of the intestinal mucosa: curioser and curioser. Semin Immunol 1991; 3:99-108.
145. Sydora BC, Mixter PF, Holcombe HR, Eghtesady P, Williams K, Amaral MC, Nel A, Kroenberg M. IELs are activated and cytolytic but do not proliferate as well as other T cells in response to mitogenic stimulation. J Immunol 1993; 150(6):2179-91.
146. Weiner HL, GA Mackin, M Matsui, EJ Orav, SJ Khoury, al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA. Oral tolerance: immunologic mechanisms and treatment of animal and human organspecific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol 1994; 12:809-37.
147. Higgins P, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988; 140:440-445.
148. Fuller KA, Pearl D, Whitacre CC. Oral tolerance in experimental autoimmune encephalomyelitis: serum and salivary antibody responses. J Neuroimmunol 1990; 28:15-26.
149. Lider O, Santos LMB, Lee CSY, Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8 + T lymphocytes. J Immunol 1989; 142:748-752.
150. Chen Y, Kuchroo VJ, Inobe J-I, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265:1237-1240.
151. Georgiades JA, Kruzel ML, Seman G. Transfer of antiviral resistance by spleen and blood cells of mice receiving low doses of IFN alpha or gamma. J Interferon Res 1989; 9:S213.
152. Blalock JE, Baron S, Johnson HM, Stanton GJ. Transmission of interferoninduced activities by cell to cell communication. Tex Rep Biol Med 1982; 41:344-349.
153. Butcher EC. The regulation of lymphocyte traffic. Curr Top Microbiol Immunol 1986; 128:85-122.
154. Bocci V. Roles of interferon produced in physiological conditions. Immunology 1988; 64:1-9.
155. Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Giannella G et al. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res 1990; 50:5795-5800.
156. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, et al. Tumour necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 1986; 163:1433-1450.
157. Bocci V. Absorption of cytokines via oropharyngeal-associated lymphoid tissues: Does an unorthodox route improve the therapeutic index of interferon? Clin. Pharmacokinet 1991; 21:411-417.
158. Linington C, Berger T, Perry L, Weerth S, Hinze-Selch D, Zhang Y, Li HC, Lassmann H, Wekerle H. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 1993; 23:1364-1372.